Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc is positioned favorably within the biopharmaceutical sector due to its focus on developing innovative autologous tumor infiltrating lymphocyte (TIL) therapies, which are significant in the treatment of various solid tumors. The development of its ITIL-306, which utilizes the Co-Stimulatory Antigen Receptor (CoStAR) platform, highlights the company's commitment to advancing novel cancer treatments that could meet critical unmet medical needs. As the industry anticipates positive updates from related therapies, including those from competitors in the bispecific class, Instil Bio stands to benefit from a potential uplift in investor sentiment and overall market dynamics.

Bears say

Instil Bio Inc faces substantial skepticism from investors, primarily due to the perceived minimal improvement in overall survival (OS) curves after recent updates, which has been interpreted as underwhelming progress. Additionally, the company is grappling with several risks, including potential delays in advancing its clinical candidates and the possibility of generating unfavorable clinical data for critical therapies like AXN-2510 targeted at non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Furthermore, there exists a risk of medium- to long-term dilution, which could further negatively impact investor confidence and the stock's performance.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.